Clinical Trial Update: Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ofatumumab-bendamustine versus bendamustine alone in rituximab-refractory indolent B-cell non-Hodgkin lymphoma was terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Lymphoma Follicular

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab Bendamustine (ofatumumab-bendamustine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphoma, Follicular | Phase 3 | Status: TERMINATED | Results posted: 2020-03-27